In particular, the validation of DAS28-MCP-1 against DAS28-ESR, DAS28-CRP and SDAI in monitoring the responses of medications, especially biologics (above all, Tocilizumab users)26, in rheumatoid arthritis is much needed. This evidence concerns the gene CCL2 and rheumatoid arthritis.